Company Profile
Ambrx Biopharma Stock Price, News & Analysis
- Ticker:
- AMAM
- Exchange:
- NYSE
- Sector:
- Biopharma
- Location:
- United States
Why the stock is moving
Current closing-price context is not available for AMAM.
Company overview
Business overview
Ambrx Biopharma was an antibody-drug conjugate company focused on precision oncology before being acquired by Johnson & Johnson. Its platform centered on engineered biologics and targeted payload delivery.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ before acquisition, Ambrx sat in oncology biotechnology.
Business Model Characteristics
The business relied on ADC development, clinical data, and the strategic value of its biologic engineering platform.
Position Within the Biotechnology Landscape
Ambrx was a differentiated ADC name and now belongs to biotech M&A history.
Future catalysts
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What does Ambrx Biopharma do?
Ambrx Biopharma was an antibody-drug conjugate company focused on precision oncology before being acquired by Johnson & Johnson. Its platform centered on engineered biologics and targeted payload delivery.
On which exchange is AMAM stock listed?
Ambrx Biopharma (AMAM) is associated with NYSE, United States, Biopharma.
What is Ambrx?
Ambrx Biopharma was an antibody-drug conjugate company focused on precision oncology before being acquired by Johnson & Johnson.
Which conditions is Ambrx Biopharma targeting with Ambrx?
Ambrx Biopharma is associated with oncology based on its company overview and current catalyst commentary.
What is Biopharma?
Ambrx Biopharma was an antibody-drug conjugate company focused on precision oncology before being acquired by Johnson & Johnson.
What is Johnson?
Ambrx Biopharma was an antibody-drug conjugate company focused on precision oncology before being acquired by Johnson & Johnson.